QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:ENSC

Ensysce Biosciences - ENSC Stock Forecast, Price & News

$0.50
-0.03 (-5.63%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.49
$0.55
50-Day Range
$0.42
$0.87
52-Week Range
$0.39
$7.00
Volume
466,886 shs
Average Volume
1.08 million shs
Market Capitalization
$18.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Ensysce Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
695.9% Upside
$4.00 Price Target
Short Interest
Healthy
2.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Ensysce Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.73) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

605th out of 1,112 stocks

Pharmaceutical Preparations Industry

307th out of 544 stocks

About Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Ensysce Biosciences Stock Down 5.9 %

Shares of ENSC Stock traded down $0.03 during trading hours on Thursday, hitting $0.50. 466,886 shares of the company's stock traded hands, compared to its average volume of 1,078,000. The stock's fifty day simple moving average is $0.54 and its two-hundred day simple moving average is $0.91. Ensysce Biosciences has a 12-month low of $0.39 and a 12-month high of $7.00. The stock has a market cap of $18.34 million, a price-to-earnings ratio of -0.39 and a beta of -0.07. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 1.43.

Ensysce Biosciences (NASDAQ:ENSC - Get Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.20) EPS for the quarter, hitting analysts' consensus estimates of ($0.20). The company had revenue of $0.60 million during the quarter, compared to the consensus estimate of $1.10 million. On average, analysts expect that Ensysce Biosciences will post -0.73 EPS for the current year.

Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Stock News Headlines

ENSC: Test Results Encouraging in Opioid Fight
Ensysce Biosciences appoints Dr. Nily Osman as CMO
ENSC: Ensysce Releases Encouraging Financials
Ensysce Biosciences reports Q4 results
See More Headlines
Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Company Calendar

Today
8/11/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENSC
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+695.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-29,080,000.00
Net Margins
-788.03%
Pretax Margin
-751.42%

Debt

Sales & Book Value

Annual Sales
$3.53 million
Book Value
($0.34) per share

Miscellaneous

Free Float
17,264,000
Market Cap
$18.34 million
Optionable
Not Optionable
Beta
-0.07

Key Executives

  • Dr. D. Lynn Kirkpatrick Ph.D. (Age 65)
    Pres, CEO & Director
    Comp: $288.15k
  • Mr. David C. Humphrey CPA (Age 53)
    CFO, Sec. & Treasurer
    Comp: $308.41k
  • Mr. Geoffrey Birkett (Age 59)
    Chief Commercial Officer
    Comp: $135k
  • Dr. Jeffrey Millard Ph.d. (Age 47)
    Chief Operating Officer
  • Mr. Richard Wright M.B.A. (Age 50)
    MSE, Chief Bus. Officer
  • Dr. William K. Schmidt Ph.D. (Age 71)
    Chief Medical Officer
  • Dr. Linda Pestano Ph.D. (Age 53)
    Chief Devel. Officer
  • Dr. Nilab Osman
    Chief Medical Officer













ENSC Stock - Frequently Asked Questions

Should I buy or sell Ensysce Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENSC shares.
View ENSC analyst ratings
or view top-rated stocks.

What is Ensysce Biosciences' stock price forecast for 2022?

1 Wall Street research analysts have issued 12 month price objectives for Ensysce Biosciences' shares. Their ENSC share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 695.9% from the stock's current price.
View analysts price targets for ENSC
or view top-rated stocks among Wall Street analysts.

How have ENSC shares performed in 2022?

Ensysce Biosciences' stock was trading at $4.70 at the start of the year. Since then, ENSC shares have decreased by 89.3% and is now trading at $0.5026.
View the best growth stocks for 2022 here
.

Are investors shorting Ensysce Biosciences?

Ensysce Biosciences saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 549,200 shares, a decrease of 12.1% from the July 15th total of 624,900 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 2.9% of the company's shares are sold short.
View Ensysce Biosciences' Short Interest
.

When is Ensysce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our ENSC earnings forecast
.

What is Ensysce Biosciences' stock symbol?

Ensysce Biosciences trades on the NASDAQ under the ticker symbol "ENSC."

How do I buy shares of Ensysce Biosciences?

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ensysce Biosciences' stock price today?

One share of ENSC stock can currently be purchased for approximately $0.50.

How much money does Ensysce Biosciences make?

Ensysce Biosciences (NASDAQ:ENSC) has a market capitalization of $18.34 million and generates $3.53 million in revenue each year. The company earns $-29,080,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

How can I contact Ensysce Biosciences?

Ensysce Biosciences' mailing address is 250 WEST 57 TH STREET SUITE 415, NEW YORK NY, 10107. The official website for the company is ensysce.com. The company can be reached via phone at 858-263-4196 or via email at shannon@mzgroup.us.

This page (NASDAQ:ENSC) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.